Barclays analyst Luke Sergott raised the firm’s price target on Avantor to $26 from $23 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTR: